On Friday, Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), added 44.12% and closed at $1.96 in the last trading session. The last trading range of the stock ranges between $1.41 and $2.04. ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, recently stated positive interim data for CMX157, the Company’s highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead’s Viread®) in chronically infected hepatitis B (HBV) patients.
Patients successfully accomplished both 5 mg and 10 mg cohorts, and interim data stated below are from 10 HBV-infected patients who accomplished 14 days of once-a-day oral dosing of 25 mg of CMX157, and two HBV patients treated for 14 days of oral dosing with 300 mg TDF. The CMX157 treated patients showed an average 99% reduction in HBV viral load contrast to baseline. Significantly, the observed antiviral activity for CMX157 is comparable to that observed in TDF-treated patients, but at 1/12th the dose (25 mg CMX157 vs. standard 300 mg TDF).
Infosys Ltd ADR (NYSE:INFY), dropped -5.95% and closed at $15.96 in the last trading session. The last trading range of the stock ranges between $15.51 and $16.04. The company’s Market capitalization is $33.06 Billion with the total Outstanding Shares of 2.29 billion. Q2 sequential revenue growth at 3.5% in USD terms; 3.9% in constant currency terms
Q2 year on year revenue growth at 8.2% in USD terms; 8.9% in constant currency terms
H1 year on year revenue growth at 9.5% in stated terms; 10.5% in constant currency terms
Operating margins expanded 80 bps sequentially to 24.9%
Volume growth at 4.0% during the quarter
Q2 Utilization apart from trainees up by 200 bps sequentially to 82.5%
FY 17 revenue guidance revised to 8.0% – 9.0% in constant currency
Merged results under International Financial Reporting Standards (IFRS) for the quarter ended September 30, 2016
Quarter ended September 30, 2016
Revenues were $2,587 million for the quarter ended September 30, 2016
QoQ growth of 3.5% in stated terms; 3.9% in constant currency terms
YoY growth of 8.2% in stated terms; 8.9% in constant currency terms
Operating profit was $644 million for the quarter ended September 30, 2016
QoQ growth of 7.0%
YoY growth of 5.6%
Net profit was $539 million for the quarter ended September 30, 2016
QoQ growth of 5.5%
YoY growth of 3.8%
Earnings per share (EPS) was $0.24 for the quarter ended September 30, 2016
QoQ growth of 5.5%
YoY growth of 3.8%
Liquid assets counting cash and cash equivalents and investments were $5,349 million as on September 30, 2016 as contrast to $4,918 million as on June 30, 2016 and $4,894 million as on September 30, 2015.
The Board of Directors declared an interim dividend of INR 11 per share ($0.17 per ADS based on USD-INR rate of 66.62). The record date for interim dividend is October 24, 2016 and the payment will be made on October 26, 2016
RSP Permian Inc (NYSE:RSPP), jumped 1.08% and closed at $42.20 in the last trading session. The last trading range of the stock ranges between $40.70 and $42.72. The company’s Market capitalization is $4.34 Billion with the total Outstanding Shares of 101.64 million. During the 52-week trading session the minimum price at which share price traded, registered at $16.74 and reached to max level of $42.72. RSP Permian, Inc. (“RSP” or the “Company”) (RSPP) recently declared that it has priced an underwritten public offering of 22,000,000 shares of its common stock at $39.75 per share. The offering was upsized to 22,000,000 shares of common stock from the original offering size of 20,000,000 shares of common stock. The Company has granted the underwriters a 30-day option to purchase up to an additional 3,300,000 shares of the Company’s common stock. Total gross proceeds (before the underwriters’ discounts and commissions and estimated offering expenses) will be about $874.5 million to the Company. The offering is expected to close on October 18, 2016, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to fund a portion of the formerly declared acquisition of Silver Hill Energy Partners, LLC and Silver Hill E&P II, LLC (the “Acquisition”). The offering is not conditioned on the consummation of the Acquisition, and if the Acquisition does not occur, the net proceeds will be used for general corporate purposes, which may include funding a portion of the Company’s 2017 capital budget.
Barclays Capital Inc. and RBC Capital Markets, LLC are acting as lead joint book-running managers for the offering.